TIL (Instil Bio) NonCurrent Deferred Revenue: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TIL Instil Bio Inc TIL
29 GF Score
Price $7.50
! 3 Warning Signs
View Full Analysis

What is Instil Bio NonCurrent Deferred Revenue?

Instil Bio TIL 29 NonCurrent Deferred Revenue is $0.00 Mil as of Jun. 2026. GuruFocus rates TIL with a GF Score™ of 29/100. The stock has 3 warning signs investors should review.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Instil Bio's non-current deferred revenue for the quarter that ended in Jun. 2026 was $0.00 Mil.

Instil Bio NonCurrent Deferred Revenue Related Terms

Instil Bio NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Instil Bio's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Instil Bio NonCurrent Deferred Revenue Chart

Instil Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Instil Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TIL
29GF Score
Instil Bio Inc TIL
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of $0.00 Mil mean?
Instil Bio (TIL) has a NonCurrent Deferred Revenue of $0.00 Mil as of Jun. 2026. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Instil Bio and its competitors.
Is Instil Bio's NonCurrent Deferred Revenue too high?
Instil Bio's current NonCurrent Deferred Revenue is $0.00 Mil. Overall, Instil Bio has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Instil Bio's NonCurrent Deferred Revenue compare to ATYR and AURX?
Instil Bio's NonCurrent Deferred Revenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Biotechnology company?
A good NonCurrent Deferred Revenue depends on the Biotechnology industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Instil Bio and its competitors. Instil Bio's current NonCurrent Deferred Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instil Bio stock overvalued right now?
Instil Bio (TIL) has a current NonCurrent Deferred Revenue of $0.00 Mil. The current NonCurrent Deferred Revenue is $0.00 Mil. Instil Bio's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Instil Bio (TIL), the current NonCurrent Deferred Revenue is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Instil Bio Business Description

Address 3963 Maple Avenue, Suite 350, Dallas, TX, USA, 75219
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
29GF Score

Get the complete analysis for TIL

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.50
Price